Paper Details

  1. Home
  2. Paper Details

Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis.

Author: KuoHsiao-Huai, LeeYing-Hsiang, LinChien-Yu, LinPo-Lin, LiuLawrence Yu-Min, LiuMing-En, WangKuang-Te

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review and meta-analysis investigated the effects of lorcaserin, a selective serotonin 2c receptor agonist, on blood pressure, heart rate, and other metabolic parameters in overweight and obese patients. The aim was to assess whether lorcaserin, approved for weight loss, had additional cardiometabolic benefits.
Paper Details　
Original Abstract of the Article :
Lorcaserin is a selective serotonin 2c receptor agonist approved as an anti-obesity agent. The additional cardiometabolic benefits associated with lorcaserin have not been conclusively established. The aim of the systematic review and meta-analysis is to examine the effects of lorcaserin on blood pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jcpt.13047

データ提供：米国国立医学図書館（NLM）

Lorcaserin: A Potential Tool for Cardiometabolic Risk Management

This systematic review and meta-analysis investigated the effects of lorcaserin, a selective serotonin 2c receptor agonist approved for weight management, on cardiometabolic risk factors. Obesity is a major public health concern, and understanding the potential impact of weight-loss medications on cardiovascular health is crucial.

Lorcaserin: A Potential Tool for Cardiometabolic Risk Management

The meta-analysis found that lorcaserin had beneficial effects on blood pressure and other metabolic parameters in overweight and obese patients. It's like finding a hidden spring in the desert, offering a refreshing and potentially life-saving solution for managing cardiometabolic risks.

Managing Cardiometabolic Risks: A Multi-pronged Approach

This study highlights the importance of managing cardiometabolic risks in individuals with obesity. It's like navigating a desert landscape, understanding the different factors that can contribute to these health challenges and employing appropriate strategies to mitigate risks.

Dr.Camel's Conclusion

This study reminds me of the ongoing journey to address the global obesity epidemic. It's like a camel traversing the vast desert of health research, seeking out new and effective solutions for managing weight and preventing related health problems.
Date :
  1. Date Completed 2020-10-07
  2. Date Revised 2020-10-07
Further Info :

Pubmed ID

31544267

DOI: Digital Object Identifier

10.1111/jcpt.13047

Related Literature

Article Analysis
・Effects of lorcaserin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.